info:eu-repo/semantics/article
Identification of coinfections by viral and bacterial pathogens in covid-19 hospitalized patients in peru: Molecular diagnosis and clinical characteristics
Fecha
2021-11-01Registro en:
10.3390/antibiotics10111358
20796382
Antibiotics
2-s2.0-85118939573
SCOPUS_ID:85118939573
0000 0001 2196 144X
Autor
Pérez-Lazo, Giancarlo
Silva-Caso, Wilmer
Del Valle-Mendoza, Juana
Morales-Moreno, Adriana
Ballena-López, José
Soto-Febres, Fernando
Martins-Luna, Johanna
Carrillo-Ng, Hugo
Del Valle, Luís J.
Kym, Sungmin
Aguilar-Luis, Miguel Angel
Peña-Tuesta, Issac
Tinco-Valdez, Carmen
Illescas, Luis Ricardo
Institución
Resumen
The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.